1 Incredible Reason to Buy Vertex Pharmaceuticals Stock in November

• Vertex's halfway concern continues to thrust beardown fiscal results.

• The biotech has an breathtaking late-stage pipeline that could marque important advancement successful the adjacent fewer years.

• 10 stocks we similar amended than Vertex Pharmaceuticals ›

Vertex Pharmaceuticals (NASDAQ: VRTX) has not performed good for astir of the year, and the company's latest quarterly update did thing to crook things around. However, the marketplace whitethorn beryllium overlooking immoderate important catalysts that should jolt the banal implicit the mean term, making the company's shares a bargain this period arsenic they stay importantly down implicit the trailing-12-month period.

Vertex Pharmaceuticals continues to make astir of its gross from its cystic fibrosis (CF) franchise. The company's medicines successful this tract are undisputed leaders, driving coagulated top-line growth. However, galore investors are disquieted that Vertex Pharmaceuticals is simply a one-trick pony. The drugmaker has tried to diversify its lineup successful the past fewer years. In fact, it was successful. But newer products inactive aren't having a meaningful interaction connected its results.

That said, 1 of them, Journavx, was approved lone successful January. It has plentifulness of clip to summation traction. Furthermore, determination is an adjacent much compelling crushed to bargain the banal close now: the company's promising late-stage objective work. Vertex Pharmaceuticals has respective signifier 3 programs that could gain support successful the adjacent fewer years, importantly boosting its revenue. The archetypal is zimislecel, an investigational therapy for Type 1 diabetes (T1D).

This medicine could beryllium a functional cure for eligible patients, restoring their quality to nutrient their ain insulin. Vertex plans to taxable regulatory applications for support adjacent year.

Then determination is inaxaplin, a medicine for APOL-1 mediated kidney illness (AMKD). Vertex Pharmaceuticals' enactment successful this tract is close up its alley: The institution seeks to make drugs wherever determination are precocious unmet needs. There are presently nary approved to dainty the underlying causes of AMKD, and Vertex could beryllium looking astatine an addressable marketplace of 250,000, which is good supra the full for its highly profitable CF franchise.

Then determination is povetacicept, an investigational medicine for IgA nephropathy (a kidney disease) that is besides successful signifier 3 studies. Here too, determination are nary therapies that dainty the underlying causes, and Vertex estimates a imaginable marketplace of implicit a cardinal patients. Significant objective advancement crossed the company's late-stage pipeline successful the adjacent fewer years -- starring to the eventual support of brand-new products -- could beryllium a important catalyst for the biotech.